Key Highlights

  • Shares climbed 125p to close at 1,775p, a gain of 7.46%, lifting Market Value to roughly £94m
  • Interim Revenue for the six months to 31 December 2025 was £6.16m, down from £6.73m a year earlier
  • Profit after tax came in at £3.625m, with the Interim Dividend held at 70p per share
  • Tau-related antibody revenue rose to around £150,000 from just £30,000, a fivefold increase
  • The company closed the half-year with £5.3m of cash and no debt

Bioventix has spent much of the past year sliding from its 2025 highs, yet the Farnham-based antibody specialist remains one of AIM's most profitable and cash-generative businesses. A near-7.5% jump has put the diagnostics minnow back on investors' radar.

A sharp move off depressed levels

Shares in Bioventix (LSE:BVXP) climbed 125p to close at 1,775p on 20 August 2026, a gain of 7.46% that stood out against an otherwise quiet late-summer session for AIM. The move lifted the market value of the antibody developer to roughly £94m, spread across a little over 5.2 million shares in issue.

The bounce is more striking when set against the past year. Bioventix touched a 52-week high of 2,525p as recently as September 2025 before grinding steadily lower, bottoming at 1,350p in March 2026. Even after this rally the stock sits well below where it started the period, so the latest session looks like a recovery from depressed levels rather than a decisive change of direction.

There was no single company announcement on the day that obviously accounts for the move. Bioventix's financial year runs to 30 June, and its full-year results are not usually published until the autumn, meaning the calendar was empty of scheduled news. The rise came on modest turnover of fewer than 9,000 shares, a reminder that in a tightly held AIM company even limited buying can shift the price. The most honest reading is that investors were reassessing a heavily de-rated but still highly profitable business, rather than reacting to a fresh catalyst.

What the Business actually does

Bioventix occupies an unusual and profitable niche. It creates sheep monoclonal antibodies (SMAs) used in the automated blood-testing machines run by the big in-vitro diagnostics (IVD) companies. Those antibodies sit inside high-volume clinical tests for conditions ranging from vitamin D deficiency to thyroid function and cardiac damage. Crucially, Bioventix earns royalties on the tests its antibodies enable, so revenue accrues year after year from a small Research and Development base. The result is a business with very high margins and strong cash conversion.

The company's largest single product remains its vitamin D antibody, a mature line that has underpinned Earnings for years. Its most closely watched growth hope is troponin, the marker used in high-sensitivity tests for heart attacks, where Bioventix supplies antibodies to Siemens Healthineers and others. A newer and more speculative strand is the group's neuro or Tau antibody work, aimed at the emerging market for blood-based Alzheimer's diagnostics.

The latest verified figures

In its unaudited interim results for the six months to 31 December 2025, Bioventix reported revenue of £6.16m, down from £6.73m a year earlier, with the company noting that on a constant-currency basis the figure was closer to £6.4m. Profit before tax eased to £4.85m from £5.05m, and profit after tax came in at £3.625m against £3.772m. Basic Earnings Per Share were 69.38p, down from 72.27p.

Despite the softer top line, the Balance Sheet stayed robust, with a closing cash position of £5.3m and no debt. The board held the interim dividend at 70p per share, matching the prior year, with payment made in April 2026. Management said it remained confident in the outlook for the year to 30 June 2026.

The product detail was mixed. Troponin royalties were described as "steady", with no material uplift yet despite an FDA approval secured in late 2024 that management hopes will eventually broaden usage. Vitamin D and the core antibody portfolio were broadly in line with the prior year. The bright spot was the neuro franchise: Tau-related antibody revenue rose to around £150,000 from just £30,000, a fivefold increase, as several major IVD and high-sensitivity platform companies incorporated Bioventix's antibodies into phospho-Tau217 assay designs that currently remain research-use-only.

For context, in the year to 30 June 2025 earnings per share slipped 6.3% to 143.29p while the company paid total dividends of 150p, meaning the distribution modestly exceeded reported earnings — a point income-focused holders will be watching closely.

What could drive the shares next

The clearest potential catalyst is troponin. Bioventix has long argued that wider adoption of high-sensitivity cardiac testing, helped by regulatory clearances, could lift Royalty income, and any evidence of that finally translating into revenue growth in the forthcoming full-year figures could shift sentiment.

The Alzheimer's angle is the bigger prize but also the more distant one. Blood-based diagnostics for neurodegenerative disease are a fast-developing field, and if the phospho-Tau217 assays that use Bioventix antibodies move from research use into routine clinical testing, the current five- and six-figure sums could scale meaningfully. That transition, however, depends on decisions taken by the company's IVD customers rather than by Bioventix itself.

There is also a simpler valuation argument. After a heavy de-rating, the stock trades on a far lower multiple than it commanded at its peak, and its combination of high margins, net cash and a substantial Dividend Yield may attract income investors if confidence in the earnings base returns.

Risks investors should watch

The interim results made plain that revenue has been drifting lower, and the long-promised troponin recovery has yet to arrive. A continued failure to reignite growth in the core portfolio would keep pressure on both earnings and the dividend, which has recently been running at or above reported profits.

Geopolitical and trade dynamics are a genuine, company-specific concern. Bioventix has repeatedly flagged that onshoring trends and "China First" style policies favouring local manufacturers could erode a slice of its addressable market over time. Currency swings also matter, given that a large share of royalties is earned in dollars and euros.

Finally, this is a small, tightly held AIM stock. Daily volumes are thin, the spread can be wide, and the business is concentrated in a handful of key products and customers. Those features cut both ways: they can amplify moves like the one seen on 20 August, but they also make the shares harder to trade in size and more exposed to any single customer decision.

Investor takeaway

Bioventix remains a rare thing on AIM — a consistently profitable, cash-generative and dividend-paying business — but the past year has shown that even quality niche operators can de-rate sharply when growth stalls. The 7.46% rise restores some ground without resolving the central question of whether troponin and Alzheimer's testing can return the group to growth.

With full-year results to 30 June 2026 due in the autumn, the near-term focus falls on those numbers: the trajectory of royalty income, the health of the dividend relative to earnings, and any hard evidence that the neuro Franchise is scaling. Investors will be watching whether this session marks the start of a genuine recovery for Bioventix (LSE:BVXP) or simply another twitch in a volatile, Illiquid small cap.